Literature DB >> 30980225

The Na+K+-ATPase Inhibitor Marinobufagenin and Early Cardiovascular Risk in Humans: a Review of Recent Evidence.

Michél Strauss1, Wayne Smith1,2, Olga V Fedorova3, Aletta E Schutte4,5.   

Abstract

PURPOSE OF REVIEW: This review synthesizes recent findings in humans pertaining to the relationships between marinobufagenin (MBG), a steroidal Na+/K+-ATPase inhibitor and salt-sensitivity biomarker, and early cardiovascular risk markers. RECENT
FINDINGS: Twenty-four-hour urinary MBG strongly associates with habitual salt intake in young healthy adults (aged 20-30 years). Furthermore, in young healthy adults free of detected cardiovascular disease, MBG associates with increased large artery stiffness and left ventricular mass independent of blood pressure. These findings in human studies corroborate mechanistic data from rat studies whereby stimulation of MBG by a high salt intake or MBG infusion increased vascular fibrosis and cardiac hypertrophy. Twenty-four-hour urinary MBG may be a potential biomarker of early cardiovascular risk. Adverse associations between MBG-which increases with salt consumption-and early cardiovascular risk markers support the global efforts to reduce population-wide salt intake in an effort to prevent and control the burden of non-communicable diseases.

Entities:  

Keywords:  Early cardiovascular risk; Humans; Marinobufagenin; Salt-sensitivity; Women

Mesh:

Substances:

Year:  2019        PMID: 30980225      PMCID: PMC6590998          DOI: 10.1007/s11906-019-0942-y

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  79 in total

Review 1.  Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms.

Authors:  Wilmer W Nichols
Journal:  Am J Hypertens       Date:  2005-01       Impact factor: 2.689

2.  Marinobufagenin, an endogenous alpha-1 sodium pump ligand, in hypertensive Dahl salt-sensitive rats.

Authors:  O V Fedorova; N I Kolodkin; N I Agalakova; E G Lakatta; A Y Bagrov
Journal:  Hypertension       Date:  2001-02       Impact factor: 10.190

3.  Myocardial PKC beta2 and the sensitivity of Na/K-ATPase to marinobufagenin are reduced by cicletanine in Dahl hypertension.

Authors:  Olga V Fedorova; Mark I Talan; Natalia I Agalakova; Marie-Therese Droy-Lefaix; Edward G Lakatta; Alexei Y Bagrov
Journal:  Hypertension       Date:  2003-02-10       Impact factor: 10.190

4.  Overweight and sympathetic overactivity in black Americans.

Authors:  N I Abate; Y H Mansour; M Tuncel; D Arbique; B Chavoshan; A Kizilbash; T Howell-Stampley; W Vongpatanasin; R G Victor
Journal:  Hypertension       Date:  2001-09       Impact factor: 10.190

5.  Racial differences in resting end-tidal CO2 and circulating sodium pump inhibitor.

Authors:  D E Anderson; A Scuteri; N Agalakova; D J Parsons; A Y Bagrov
Journal:  Am J Hypertens       Date:  2001-08       Impact factor: 2.689

6.  Endogenous Na,K pump ligands are differentially regulated during acute NaCl loading of Dahl rats.

Authors:  O V Fedorova; E G Lakatta; A Y Bagrov
Journal:  Circulation       Date:  2000-12-12       Impact factor: 29.690

7.  Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia.

Authors:  D A Lopatin; E K Ailamazian; R I Dmitrieva; V M Shpen; O V Fedorova; P A Doris; A Y Bagrov
Journal:  J Hypertens       Date:  1999-08       Impact factor: 4.844

8.  Endogenous ligand of alpha(1) sodium pump, marinobufagenin, is a novel mediator of sodium chloride--dependent hypertension.

Authors:  Olga V Fedorova; Mark I Talan; Natalia I Agalakova; Edward G Lakatta; Alexei Y Bagrov
Journal:  Circulation       Date:  2002-03-05       Impact factor: 29.690

9.  Coordinated shifts in Na/K-ATPase isoforms and their endogenous ligands during cardiac hypertrophy and failure in NaCl-sensitive hypertension.

Authors:  Olga V Fedorova; Mark I Talan; Natalia I Agalakova; Edward G Lakatta; Alexei Y Bagrov
Journal:  J Hypertens       Date:  2004-02       Impact factor: 4.844

10.  Sodium retention in black and white female adolescents in response to salt intake.

Authors:  Cristina Palacios; Karin Wigertz; Berdine R Martin; Lisa Jackman; J Howard Pratt; Munro Peacock; George McCabe; Connie M Weaver
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

View more
  4 in total

Review 1.  Research Progress in Pharmacological Activities and Applications of Cardiotonic Steroids.

Authors:  Junwei Ren; Xinyuan Gao; Xi Guo; Ning Wang; Xin Wang
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

2.  The Cardiotonic Steroid Marinobufagenin Is a Predictor of Increased Left Ventricular Mass in Obesity: The African-PREDICT Study.

Authors:  Michél Strauss-Kruger; Ruan Kruger; Wayne Smith; Lebo F Gafane-Matemane; Gontse Mokwatsi; Wen Wei; Olga V Fedorova; Aletta E Schutte
Journal:  Nutrients       Date:  2020-10-18       Impact factor: 5.717

3.  Integrated network pharmacology and molecular docking approaches to reveal the synergistic mechanism of multiple components in Venenum Bufonis for ameliorating heart failure.

Authors:  Wei Ren; Zhiqiang Luo; Fulu Pan; Jiali Liu; Qin Sun; Gang Luo; Raoqiong Wang; Haiyu Zhao; Baolin Bian; Xiao Xiao; Qingrong Pu; Sijin Yang; Guohua Yu
Journal:  PeerJ       Date:  2020-10-30       Impact factor: 2.984

4.  Canrenone Restores Vasorelaxation Impaired by Marinobufagenin in Human Preeclampsia.

Authors:  Natalia I Agalakova; Yulia N Grigorova; Ivan A Ershov; Vitaly A Reznik; Elena V Mikhailova; Olga V Nadei; Leticia Samuilovskaya; Larisa A Romanova; C David Adair; Irina V Romanova; Alexei Y Bagrov
Journal:  Int J Mol Sci       Date:  2022-03-19       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.